January 28, 2025 03:29 PM EST

AstraZeneca and Daiichi Sankyo's Enhertu approved in 'ultralow' HER2 patients

Nicole DeFeudis

Editor

AstraZeneca and Daiichi Sankyo’s antibody-drug conjugate Enhertu is now approved to treat a new subset of breast cancer patients with very low levels of HER2 …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

AstraZeneca and Daiichi Sankyo's Enhertu approved in 'ultralow' HER2 patients

Nicole DeFeudis

Editor

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

RFK blog: Kennedy survives Senate grilling, with no bombshells to derail HHS confirmation

Trump administration makes first comments on how it will run IRA drug negotiations

Updated: Zentalis lays off 40% of staff, whittles down indications for WEE1 inhibitor

23andMe weighs a sale as cash dwindles

8VC, a tech and life sciences VC firm behind Altos Labs, eyes $1B fund

Why the premier recruitment agency in the world is giving up recruiting, and sponsors should, too

As­traZeneca and Dai­ichi Sanky­o's En­her­tu ap­proved in 'ul­tralow' HER2 pa­tients

Editor

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

AstraZeneca and Daiichi Sankyo's Enhertu approved in 'ultralow' HER2 patients